NASDAQ:ALVR AlloVir - ALVR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $4.43 -0.12 (-2.64%) (As of 03/20/2023 02:24 PM ET) Add Compare Share Share Today's Range$3.93▼$4.4450-Day Range$4.55▼$7.0552-Week Range$3.17▼$10.29Volume408,296 shsAverage Volume275,801 shsMarket Capitalization$414.03 millionP/E RatioN/ADividend YieldN/APrice Target$24.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media AlloVir MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside449.3% Upside$24.33 Price TargetShort InterestBearish5.80% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$219,126 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.89) to ($1.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.69 out of 5 starsMedical Sector818th out of 983 stocksBiological Products, Except Diagnostic Industry141st out of 161 stocks 3.5 Analyst's Opinion Consensus RatingAlloVir has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.33, AlloVir has a forecasted upside of 449.3% from its current price of $4.43.Amount of Analyst CoverageAlloVir has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted5.80% of the outstanding shares of AlloVir have been sold short.Short Interest Ratio / Days to CoverAlloVir has a short interest ratio ("days to cover") of 21.1, which indicates bearish sentiment.Change versus previous monthShort interest in AlloVir has recently increased by 20.44%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlloVir does not currently pay a dividend.Dividend GrowthAlloVir does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALVR. Previous Next 2.2 News and Social Media Coverage News SentimentAlloVir has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.35 average news sentiment score of Medical companies.Search InterestOnly 10 people have searched for ALVR on MarketBeat in the last 30 days. This is a decrease of -52% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AlloVir insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $219,126.00 in company stock.Percentage Held by Insiders54.22% of the stock of AlloVir is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for AlloVir are expected to decrease in the coming year, from ($1.89) to ($1.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AlloVir is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AlloVir is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlloVir has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About AlloVir (NASDAQ:ALVR) StockAllovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.Read More Receive ALVR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AlloVir and its competitors with MarketBeat's FREE daily newsletter. Email Address ALVR Stock News HeadlinesFebruary 23, 2023 | finance.yahoo.comAlloVir Appoints Derek Adams, Ph.D., to Board of DirectorsFebruary 18, 2023 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on AlloVir (ALVR)March 20, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!February 13, 2023 | msn.comWall Street Analysts Predict a 281.43% Upside in AlloVir, Inc. (ALVR): Here's What You Should KnowFebruary 10, 2023 | finance.yahoo.comWall Street Analysts Predict a 281.43% Upside in AlloVir, Inc. (ALVR): Here's What You Should KnowFebruary 1, 2023 | finance.yahoo.comAlloVir to Participate in the SVB Securities Global Biopharma ConferenceJanuary 25, 2023 | finance.yahoo.comAre Medical Stocks Lagging Adicet Bio (ACET) This Year?January 25, 2023 | finance.yahoo.comHow Much Upside is Left in AlloVir, Inc. (ALVR)? Wall Street Analysts Think 355.8%March 20, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!January 25, 2023 | finance.yahoo.comAlloVir, Inc. (ALVR) Upgraded to Buy: Here's What You Should KnowJanuary 9, 2023 | finance.yahoo.comAlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023January 3, 2023 | finance.yahoo.comAlloVir to Present at the 41st Annual J.P. Morgan Healthcare ConferenceJanuary 1, 2023 | finance.yahoo.comAlloVir, Inc. (ALVR) Stock Historical Prices & Data - Yahoo FinanceDecember 10, 2022 | finance.yahoo.comAlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation at the 64th ASH Annual Meeting and ExpositionNovember 15, 2022 | finance.yahoo.comAlloVir to Participate in the Piper Sandler 34th Annual Healthcare ConferenceNovember 3, 2022 | finance.yahoo.comAlloVir Reports Third Quarter 2022 Financial ResultsNovember 3, 2022 | finance.yahoo.comFinal Data from AlloVir’s Phase 2 Study of Posoleucel for Multi-Virus Prevention to be Highlighted in Oral Presentation at 64th American Society of Hematology Annual MeetingOctober 21, 2022 | finance.yahoo.comWe Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth CarefullyOctober 10, 2022 | realmoney.thestreet.comThe 'Big Picture' Isn't Pretty - RealMoney - RealMoneySeptember 17, 2022 | reuters.comALVR.O - Allovir Inc | Stock Price & Latest News | ReutersSeptember 9, 2022 | nasdaq.comALVR Crosses Above Key Moving Average LevelSeptember 6, 2022 | nasdaq.comWall Street Analysts See a 259% Upside in AlloVir, Inc. (ALVR): Can the Stock Really Move This High? - NasdaqSeptember 6, 2022 | finance.yahoo.comWall Street Analysts See a 259% Upside in AlloVir, Inc. (ALVR): Can the Stock Really Move This High?August 31, 2022 | businesswire.comAlloVir to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference - Business WireAugust 31, 2022 | finance.yahoo.comAlloVir to Participate in the Morgan Stanley 20th Annual Global Healthcare ConferenceAugust 26, 2022 | nasdaq.comAnalysts See 25% Gains Ahead For IWN - NasdaqAugust 19, 2022 | nasdaq.comDoes AlloVir, Inc. (ALVR) Have the Potential to Rally 251% as Wall Street Analysts Expect? - NasdaqSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ALVR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AlloVir and its competitors with MarketBeat's FREE daily newsletter. Email Address ALVR Company Calendar Last Earnings8/05/2021Today3/20/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALVR CUSIPN/A CIK1754068 Webwww.allovir.com Phone617-433-2605FaxN/AEmployees107Year FoundedN/APrice Target and Rating Average Stock Price Forecast$24.33 High Stock Price Forecast$34.00 Low Stock Price Forecast$19.00 Forecasted Upside/Downside+499.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-168,710,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-81.55% Return on Assets-67.36% Debt Debt-to-Equity RatioN/A Current Ratio9.99 Quick Ratio9.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.41 per share Price / Book1.68Miscellaneous Outstanding Shares93,460,000Free Float42,787,000Market Cap$379.45 million OptionableNot Optionable Beta0.85 Key ExecutivesMr. David L. Hallal (Age 57)Exec. Chairman Comp: $395.6kDr. Diana M. Brainard M.D. (Age 52)CEO & Director Comp: $1.52MMr. Vikas Sinha C.A. (Age 60)CPA, M.B.A., Pres, CFO & Director Comp: $622.25kDr. Jeroen van Beek Ph.D. (Age 59)Consultant Comp: $601kMr. Agustin Melian M.D. (Age 59)Advisor Comp: $1.37MMr. Brett R. Hagen (Age 50)Chief Accounting Officer Mr. Dana M. Alexander M.B.A. (Age 47)Sr. VP of Technical Operations Dr. Ann M. Leen Ph.D. (Age 46)Chief Scientific Officer Ms. Sonia ChoiSr. VP of Corp. Affairs & Investor RelationsMr. Edward Miller J.D. (Age 58)Gen. Counsel & Sec. More ExecutivesKey CompetitorsMesoblastNASDAQ:MESOCompass TherapeuticsNASDAQ:CMPXCullinan OncologyNASDAQ:CGEMNovavaxNASDAQ:NVAXCoherus BioSciencesNASDAQ:CHRSView All CompetitorsInsiders & InstitutionsAlliancebernstein L.P.Bought 10,500 shares on 2/16/2023Ownership: 0.042%Point72 Middle East FZEBought 4,988 shares on 2/16/2023Ownership: 0.005%Alps Advisors Inc.Bought 12,321 shares on 2/15/2023Ownership: 0.068%Millennium Management LLCBought 26,878 shares on 2/15/2023Ownership: 0.029%Jane Street Group LLCSold 4,355 shares on 2/15/2023Ownership: 0.025%View All Insider TransactionsView All Institutional Transactions ALVR Stock - Frequently Asked Questions Should I buy or sell AlloVir stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AlloVir in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALVR shares. View ALVR analyst ratings or view top-rated stocks. What is AlloVir's stock price forecast for 2023? 3 equities research analysts have issued twelve-month price targets for AlloVir's shares. Their ALVR share price forecasts range from $19.00 to $34.00. On average, they expect the company's stock price to reach $24.33 in the next year. This suggests a possible upside of 499.3% from the stock's current price. View analysts price targets for ALVR or view top-rated stocks among Wall Street analysts. How have ALVR shares performed in 2023? AlloVir's stock was trading at $5.13 at the beginning of the year. Since then, ALVR shares have decreased by 20.9% and is now trading at $4.06. View the best growth stocks for 2023 here. Are investors shorting AlloVir? AlloVir saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 5,420,000 shares, an increase of 20.4% from the February 13th total of 4,500,000 shares. Based on an average daily volume of 257,100 shares, the days-to-cover ratio is currently 21.1 days. View AlloVir's Short Interest. When is AlloVir's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our ALVR earnings forecast. How were AlloVir's earnings last quarter? AlloVir, Inc. (NASDAQ:ALVR) posted its earnings results on Thursday, August, 5th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.46) by $0.14. What ETFs hold AlloVir's stock? ETFs with the largest weight of AlloVir (NASDAQ:ALVR) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), Principal Healthcare Innovators ETF (BTEC), ProShares Ultra Nasdaq Biotechnology (BIB) and Invesco Nasdaq Biotechnology ETF (IBBQ), What other stocks do shareholders of AlloVir own? Based on aggregate information from My MarketBeat watchlists, some companies that other AlloVir investors own include Advanced Micro Devices (AMD), Cloudera (CLDR), Infinera (INFN), Sonos (SONO), Trevena (TRVN), Abbott Laboratories (ABT), Boeing (BA), Delta Air Lines (DAL), Datadog (DDOG) and FuelCell Energy (FCEL). When did AlloVir IPO? (ALVR) raised $252 million in an IPO on Thursday, July 30th 2020. The company issued 14,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO. What is AlloVir's stock symbol? AlloVir trades on the NASDAQ under the ticker symbol "ALVR." Who are AlloVir's major shareholders? AlloVir's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Alkeon Capital Management LLC (4.94%), JPMorgan Chase & Co. (1.03%), Geode Capital Management LLC (0.82%), Renaissance Technologies LLC (0.44%), Charles Schwab Investment Management Inc. (0.33%) and Morgan Stanley (0.24%). Insiders that own company stock include Agustin Melian, Ann M Leen, Beek Jeroen B Van, Beek Jeroen B Van, Brett R Hagen, David Hallal, Diana Brainard, Edward Miller, Ercem Atillasoy, Jeffrey S Bornstein, John Robert Wilson, Juan Vera, Morana Jovan-Embiricos and Vikas Sinha. View institutional ownership trends. How do I buy shares of AlloVir? Shares of ALVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AlloVir's stock price today? One share of ALVR stock can currently be purchased for approximately $4.06. How much money does AlloVir make? AlloVir (NASDAQ:ALVR) has a market capitalization of $379.45 million. The company earns $-168,710,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. How many employees does AlloVir have? The company employs 107 workers across the globe. How can I contact AlloVir? AlloVir's mailing address is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. The official website for the company is www.allovir.com. The company can be reached via phone at 617-433-2605 or via email at ir@allovir.com. This page (NASDAQ:ALVR) was last updated on 3/20/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.